Skip to main content

Myriad Genetics Introduces its Diagnostic Products to Brazilian Market

SAN FRANCISCO, Nov. 14 – Myriad Genetics will market its predictive medicine products in Brazil through Sao Paulo-based Fleury Laboratories, the companies announced Wednesday.

The initial products marketed in Brazil from the Salt Lake City-based company will be cancer prediction kits, including ones to detect mutations for types of breast, skin, and colon cancer.

Financial details of the agreement were not disclosed.

Fleury Laboratories has 1,300 employees and 15 clinics throughout Brazil, according to the company.

Earlier in the month, Myriad reported a 22 percent rise in its revenue for the first quarter , from $10.8 million for the first quarter in 2000 to $13.2 million in 2001.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.